Sun et al. demonstrated positive results not only for TS-negative patients but also for adenocarcinoma-only patients treated with pemetrexed-based therapy (median PFS 2.9 versus 1.4 months, P = 0.001) [34]. Here, TYMS is linked to adenocarcinoma.